Bristol-Myers Squibb Co (NYSE:BMY) – Investment analysts at William Blair lifted their Q1 2019 earnings per share estimates for Bristol-Myers Squibb in a report released on Thursday, March 14th. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will earn $1.14 per share for the quarter, up from their prior estimate of $0.94. William Blair has a “Outperform” rating on the stock.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.09. Bristol-Myers Squibb had a return on equity of 48.99% and a net margin of 21.95%. The business had revenue of $5.97 billion for the quarter, compared to analyst estimates of $5.95 billion. During the same quarter in the previous year, the firm earned $0.68 earnings per share. The company’s revenue was up 9.6% on a year-over-year basis.

Other equities research analysts have also issued research reports about the company. ValuEngine upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Friday, December 7th. Bank of America dropped their price target on Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 19th. Edward Jones lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Friday, January 4th. Credit Suisse Group reiterated a “hold” rating and issued a $59.00 target price on shares of Bristol-Myers Squibb in a research report on Thursday, December 13th. Finally, Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $60.00 target price on the stock in a research report on Tuesday, March 5th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $59.40.

Shares of BMY stock opened at $49.60 on Monday. Bristol-Myers Squibb has a fifty-two week low of $44.30 and a fifty-two week high of $67.16. The stock has a market cap of $81.41 billion, a PE ratio of 12.46, a price-to-earnings-growth ratio of 2.55 and a beta of 0.81. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.50 and a current ratio of 1.61.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be given a $0.41 dividend. The ex-dividend date is Thursday, April 4th. This represents a $1.64 dividend on an annualized basis and a yield of 3.31%. Bristol-Myers Squibb’s dividend payout ratio is currently 41.21%.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Capital Financial Planning LLC purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth approximately $28,000. Well Done LLC purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth approximately $30,000. Riverview Trust Co purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth approximately $33,000. Portfolio Solutions LLC purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth approximately $37,000. Finally, Gantzert Investment Co. LLC ADV purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth approximately $39,000. Hedge funds and other institutional investors own 73.14% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

See Also: Futures Contract

Earnings History and Estimates for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.